ABSTRACT We examined the bronchodilator responses to inhalation of salbutamol (200 ,g) and of ipratropium bromide (40 jg) in the morning and in the afternoon before and during a course of oral prednisolone (40 mg daily) in 15 patients with chronic, partly reversible airflow obstruction. Bronchodilatation was assessed by measuring serial peak expiratory flow rates (PEFR) for six hours after aerL'sol drug administration and calculating the area under the time-response curves. Eleven patients were found to be corticosteroid resistant in not attaining a baseline bronchodilatation of at least 25% during corticosteroid treatment. These patients also failed to show any enhancement of their bronchodilator responses to either salbutamol or ipratropium bromide during prednisolone administration. We therefore conclude that there is no rationale for giving or continuing corticosteroid treatment in known steroid-resistant patients in the hope of nevertheless potentiating their bronchodilator responses to salbutamol or ipratropium bromide.
Corticosteroids have been used to treat airflow obstruction in acute and chronic asthma for over 30 years.'-3 Their use in chronic bronchitis is more controversial but a trial of corticosteroid treatment is often indicated.48 Evidence has been accumulating for various cellular effects of corticosteroids that may result in bronchial relaxation and it has been suggested that one possible mode of action may be by the potentiation of endogenous and exogenous catecholamines.9`" There is a subgroup of patients with partly reversible airflow obstruction in response to bronchodilator drugs who do not show bronchodilatation with corticosteroid treatment. Our study was designed to determine whether corticosteroid treatment might nevertheless be of benefit in these patients by enhancing the bronchodilatation normally achieved with either salbutamol, a ,8-adrenergic agonist related to the catecholamines, or ipratropium bromide, a parasympatholytic agent, given by pressurised aerosols in conventional doses. were compared to determine any possible specificity of potentiation of either by prednisolone.
Patients and methods
Fifteen patients (mean age 64 years) with chronic airflow obstruction were studied. All had been having long-term bronchodilator treatment but persistent symptoms were severe enough to warrant a trial of oral corticosteroid treatment. None had received oral corticosteroids during the previous month, although one patient was taking inhaled beclomethasone dipropionate, which was continued throughout. Selection criteria were: (a) evidence of airflow obstruction obtained by measuring the forced expiration in the first second (FEV,) The PEFR, although to some extent effort dependent, has been found to be as sensitive as other tests of airways obstruction in assessing bronchodilator drugs'6 and is an accepted measurement for this purpose. '7 It is known that during a trial of corticosteroid treatment in chronic airflow obstruction some improvement may be noted after three hours ' 
